Related Experiment Video
Updated: Jul 17, 2025
Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
Published on: February 9, 2021
Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis
Barry J Liang1,2, Sumiao Pang1, Robert Perttila3
1Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Abstract:
Fluorescence-guided intervention can bolster standard therapies by detecting and treating microscopic tumors before lethal recurrence. Tremendous progress in photoimmunotherapy and nanotechnology has been made to treat metastasis. However, many are lost in translation due to heterogeneous treatment effects. Here, we integrate three technological advances in targeted photo-activable multi-agent liposome (TPMAL), fluorescence-guided intervention, and laser endoscopy (ML7710) to improve photoimmunotherapy. TPMAL consists of a nanoliposome chemotherapy labeled with fluorophores for tracking and photosensitizer immunoconjugates for photoimmunotherapy. ML7710 is connected to Modulight Cloud to capture and analyze multispectral emission from TPMAL for fluorescence-guided drug delivery (FGDD) and fluorescence-guided light dosimetry (FGLD) in peritoneal carcinomatosis mouse models. FGDD revealed that TPMAL enhances drug delivery to metastases by 14-fold. ML7710 captured interpatient variability in TPMAL uptake and prompted FGLD in >50% of animals. By combining TPMAL, ML7710, and fluorescence-guided intervention, variation in treatment response was substantially reduced and tumor control improved without side effects.
Insights
This study introduces a novel photoimmunotherapy approach combining targeted photo-activable multi-agent liposomes (TPMAL) with advanced laser endoscopy (ML7710) for improved cancer treatment. The integrated system significantly reduced treatment variability and enhanced tumor control in preclinical models.
Area of Science:
- Oncology
- Nanotechnology
- Biomedical Engineering
Background:
- Fluorescence-guided intervention aids in detecting and treating microscopic tumors, preventing recurrence.
- Photoimmunotherapy and nanotechnology show promise for treating metastasis but face challenges with heterogeneous treatment effects.
- Current limitations necessitate improved methods for targeted drug delivery and precise light application in cancer therapy.
Purpose of the Study:
- To enhance photoimmunotherapy efficacy by integrating targeted photo-activable multi-agent liposome (TPMAL), fluorescence-guided intervention, and laser endoscopy (ML7710).
- To improve drug delivery, light dosimetry, and reduce treatment variability in peritoneal carcinomatosis models.
Main Methods:
- Development of TPMAL, a nanoliposome carrying chemotherapy, fluorophores, and photosensitizer immunoconjugates.
- Utilizing ML7710 connected to Modulight Cloud for capturing multispectral emission from TPMAL.
- Employing fluorescence-guided drug delivery (FGDD) and fluorescence-guided light dosimetry (FGLD) in peritoneal carcinomatosis mouse models.
Main Results:
- FGDD demonstrated a 14-fold enhancement in TPMAL drug delivery to metastases.
- ML7710 identified interpatient variability in TPMAL uptake, enabling FGLD in over 50% of animals.
- The combined approach significantly reduced treatment response variation and improved tumor control without adverse effects.
Conclusions:
- The integration of TPMAL, ML7710, and fluorescence-guided intervention offers a powerful strategy to overcome limitations in photoimmunotherapy.
- This novel system improves targeted drug delivery and precision light application, leading to enhanced therapeutic outcomes.
- The developed technology holds potential for more effective and personalized cancer treatment, particularly for metastatic disease.
